Amer Assal

2.2k total citations · 1 hit paper
32 papers, 941 citations indexed

About

Amer Assal is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Amer Assal has authored 32 papers receiving a total of 941 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 12 papers in Immunology and 10 papers in Oncology. Recurrent topics in Amer Assal's work include Hematopoietic Stem Cell Transplantation (9 papers), Immune Cell Function and Interaction (7 papers) and Acute Myeloid Leukemia Research (5 papers). Amer Assal is often cited by papers focused on Hematopoietic Stem Cell Transplantation (9 papers), Immune Cell Function and Interaction (7 papers) and Acute Myeloid Leukemia Research (5 papers). Amer Assal collaborates with scholars based in United States, United Kingdom and Saudi Arabia. Amer Assal's co-authors include Xingxing Zang, Eszter Lázár‐Molnár, Kim C. Ohaegbulam, Yu Yao, Markus Y. Mapara, Murali Janakiram, Gopichand Pendurti, Balázs Halmos, Alain Borczuk and Xiaoxin Ren and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Amer Assal

29 papers receiving 932 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

2014 654 citations Kim C. Ohaegbulam, Amer Assal et al. Trends in Molecular Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amer Assal United States	10	591	433	203	157	84	32	941
James Strauss United States	14	394 0.7×	370 0.9×	224 1.1×	88 0.6×	28 0.3×	69	837
Murali Janakiram United States	18	969 1.6×	734 1.7×	249 1.2×	196 1.2×	174 2.1×	92	1.5k
Axel Denz Germany	15	216 0.4×	608 1.4×	218 1.1×	190 1.2×	89 1.1×	42	1.0k
Joy Hsu United States	8	581 1.0×	731 1.7×	214 1.1×	100 0.6×	65 0.8×	16	1.0k
Ernesto Rossi Italy	19	446 0.8×	255 0.6×	250 1.2×	206 1.3×	25 0.3×	72	894
Jack O. Egan United States	12	386 0.7×	521 1.2×	169 0.8×	64 0.4×	166 2.0×	17	944
Silvia Calpe Netherlands	16	196 0.3×	574 1.3×	180 0.9×	109 0.7×	82 1.0×	27	904
Solveig G. Ericson United States	20	883 1.5×	182 0.4×	227 1.1×	157 1.0×	284 3.4×	67	1.4k
Yibing Peng United States	14	352 0.6×	236 0.5×	153 0.8×	99 0.6×	28 0.3×	24	642
Nicolas Pasqual France	14	779 1.3×	926 2.1×	179 0.9×	115 0.7×	24 0.3×	17	1.3k

Countries citing papers authored by Amer Assal

Since Specialization

Citations

This map shows the geographic impact of Amer Assal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amer Assal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amer Assal more than expected).

Fields of papers citing papers by Amer Assal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amer Assal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amer Assal. The network helps show where Amer Assal may publish in the future.

Co-authorship network of co-authors of Amer Assal

This figure shows the co-authorship network connecting the top 25 collaborators of Amer Assal. A scholar is included among the top collaborators of Amer Assal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amer Assal. Amer Assal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

DeFilipp, Zachariah, Hannah Choe, Yvonne A. Efebera, et al.. (2025). RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT. Blood. 146(17). 2037–2046. 1 indexed citations

Gribbin, Caitlin, Anna Alperovich, Barbara Ma, et al.. (2025). Real-world assessment of prophylactic anakinra on neurotoxicity after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysis. Blood. 146(Supplement 1). 712–712.

Migliori, Edoardo, Jianing Fu, Amer Assal, et al.. (2023). The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses. Frontiers in Immunology. 14. 1212203–1212203. 5 indexed citations

Xu, Bolong, et al.. (2023). Improved serologic responses to DTaP over Tdap vaccination in adult hematopoietic cell transplant recipients. European Journal Of Haematology. 111(3). 499–505.

Otegbeye, Folashade, Marcelo Fernández-Viña, Tao Wang, et al.. (2022). Natural Killer Cell Alloreactivity Predicted By Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch Does Not Impact Engraftment in Umbilical Cord Blood and Haploidentical Stem Cell Transplantation. Transplantation and Cellular Therapy. 28(8). 483.e1–483.e7. 2 indexed citations

Neugut, Alfred I., Divaya Bhutani, Amer Assal, et al.. (2022). The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma. Blood. 140(Supplement 1). 8026–8027. 1 indexed citations

Migliori, Edoardo, Amer Assal, Rodica Ciubotariu, et al.. (2021). Development of T-cell immunity in a liver and hematopoietic stem cell transplant recipient following coronavirus disease 2019 infection. Cytotherapy. 23(11). 980–984. 2 indexed citations

Assal, Amer, et al.. (2021). Asymmetric optic disc edema in a young patient with POEMS: A rare presentation of a rare disease. American Journal of Ophthalmology Case Reports. 22. 101064–101064.

Bansal, Rajat, Heekuk Park, Markus Y. Mapara, et al.. (2021). Antibiotic Exposure, Not Alloreactivity, Is the Major Driver of Microbiome Changes in Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(3). 135–144. 13 indexed citations

10.

Assal, Amer, et al.. (2021). Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies. Annals of Hematology. 100(7). 1863–1870. 13 indexed citations

11.

Zou, Jun, Tao Wang, Yung‐Tsi Bolon, et al.. (2021). Number of HLA-Mismatched Eplets Is Not Associated with Major Outcomes in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study. Transplantation and Cellular Therapy. 28(2). 107.e1–107.e8. 7 indexed citations

12.

Bhutani, Divaya, et al.. (2020). Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab. Clinical Lymphoma Myeloma & Leukemia. 20(4). e155–e157. 18 indexed citations

13.

Raza, Azra, Amer Assal, Abdullah Mahmood Ali, & Joseph G. Jurcic. (2020). Rewriting the rules for care of MDS and AML patients in the time of COVID-19. Leukemia Research Reports. 13. 100201–100201. 9 indexed citations

14.

Assal, Amer, et al.. (2017). Gastrointestinal Toxicity of High-Dose Melphalan in Autologous Stem-Cell Transplantation: Identification of Risk Factors and a Benchmark for Experimental Therapies. Blood. 130. 5464–5464. 1 indexed citations

15.

Assal, Amer, et al.. (2017). Risk factors and prognosis of ovarian vein thrombosis. Blood Coagulation & Fibrinolysis. 28(6). 468–474. 14 indexed citations

16.

Assal, Amer, Olga Derman, Noah Kornblum, et al.. (2016). Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy. Oncotarget. 7(32). 51981–51990. 29 indexed citations

17.

Assal, Amer, et al.. (2015). Emerging Targets in Cancer Immunotherapy: Beyond CTLA-4 and PD-1. Immunotherapy. 7(11). 1169–1186. 40 indexed citations

18.

Assal, Amer, Ashwin Sridharan, Aditi Shastri, et al.. (2015). Analysis of a large single center cohort demonstrates poor prognosis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in HIV infected patients (pts).. Journal of Clinical Oncology. 33(15_suppl). e18077–e18077. 1 indexed citations

19.

Ohaegbulam, Kim C., Amer Assal, Eszter Lázár‐Molnár, Yu Yao, & Xingxing Zang. (2014). Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine. 21(1). 24–33. 654 indexed citations breakdown →

20.

Tran, Henry, et al.. (2013). In-stent thrombosis following DDAVP administration. Blood Coagulation & Fibrinolysis. 25(1). 81–83. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact